Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 4 (2007), Issue 3 (March)

1. Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment.
   BMC Cancer, 7: 31. [Abstract] [Full-text]
2. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease.
   Thorax, 62(3): 248-52. [Abstract] [Full-text]
3. Functional CD8+ T cells infiltrate into nonsmall cell lung carcinoma.
   Cancer Immunol Immunother, 56(5): 587-600. [Abstract] [Full-text]
4. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
   J Surg Oncol, 95(4): 337-46. [Abstract] [Full-text]
5. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.
   J Surg Oncol, 95(3): 250-7. [Abstract] [Full-text]
6. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
   Int J Radiat Oncol Biol Phys, 67(4): 995-1001. [Abstract] [Full-text]
7. Spinal metastasis of occult lung carcinoma causing cauda equina syndrome.
   J Clin Neurosci, 14(4): 372-5. [Abstract] [Full-text]
8. Protein kinase C-ERK1/2 signal pathway switches glucose depletion-induced necrosis to apoptosis by regulating superoxide dismutases and suppressing reactive oxygen species production in A549 lung cancer cells.
   J Cell Physiol, 211(2): 371-85. [Abstract] [Full-text]
9. The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
   Cancer Lett, 248(1): 153-63. [Abstract] [Full-text]
10. Relationship between lung cancer and human papillomavirus in north of Iran, Mazandaran province.
    Cancer Lett, 248(1): 41-6. [Abstract] [Full-text]
11. Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways.
    Biochem Biophys Res Commun, 355(3): 807-12. [Abstract] [Full-text]
12. Pleuropulmonary blastoma, a distinctive neoplasm of childhood: report of three cases.
    Pediatr Radiol, 37(4): 337-44. [Abstract] [Full-text]
13. Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
    Cancer Treat Rev, 33(2): 101-37. [Abstract] [Full-text]
14. Association of cooking oil fumes exposure with lung cancer: involvement of inhibitor of apoptosis proteins in cell survival and proliferation in vitro.
    Mutat Res, 628(2): 107-16. [Abstract] [Full-text]
15. Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic.
    Cancer Treat Rev, 33(2): 203-12. [Abstract] [Full-text]
16. Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells.
    Cancer Lett, 248(2): 292-8. [Abstract] [Full-text]
17. Computed tomography screening and lung cancer outcomes.
    JAMA, 297(9): 953-61. [Abstract] [Full-text]
18. Lung cancer risk among female textile workers exposed to endotoxin.
    J Natl Cancer Inst, 99(5): 357-64. [Abstract] [Full-text]
19. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer.
    Oncogene, 26(11): 1616-25. [Abstract] [Full-text]
20. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.
    Oncogene, 26(11): 1567-76. [Abstract] [Full-text]
21. Telomerase expression in lung preneoplasia and neoplasia.
    Int J Cancer, 120(9): 1835-41. [Abstract] [Full-text]
22. The effects of combined antioxidant (beta-carotene, alpha-tocopherol and ascorbic acid) supplementation on antioxidant capacity, DNA single-strand breaks and levels of insulin-like growth factor-1/IGF-binding protein 3 in the ferret model of lung cancer.
    Int J Cancer, 120(9): 1847-54. [Abstract] [Full-text]
23. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin.
    Int J Cancer, 120(9): 2019-27. [Abstract] [Full-text]
24. The U.S. Public Health Service and smoking in the 1950s: the tale of two more statements.
    J Hist Med Allied Sci, 62(2): 171-212. [Abstract] [Full-text]
25. Lung cancer risk associated to exposure to radon and smoking in a case-control study of French uranium miners.
    Health Phys, 92(4): 371-8. [Abstract] [Full-text]
26. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases.
    Ann Diagn Pathol, 11(2): 89-96. [Abstract] [Full-text]
27. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer.
    Anticancer Drugs, 18(4): 471-6. [Abstract] [Full-text]
28. Fatal ischemic bowel necrosis possibly due to docetaxel and cisplatin in a patient with non-small cell lung cancer.
    Lung Cancer, 56(1): 143-4. [Abstract] [Full-text]
29. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases.
    Lung Cancer, 56(1): 51-8. [Abstract] [Full-text]
30. Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and adenocarcinoma of the lung.
    Lung Cancer, 56(1): 35-42. [Abstract] [Full-text]
31. Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.
    Lung Cancer, 56(1): 97-103. [Abstract] [Full-text]
32. A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma.
    Lung Cancer, 56(1): 89-95. [Abstract] [Full-text]
33. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Lung Cancer, 56(1): 43-50. [Abstract] [Full-text]
34. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.
    Lung Cancer, 56(1): 115-23. [Abstract] [Full-text]
35. Free breathing gated delivery (FBGD) of lung radiation therapy: analysis of factors affecting clinical patient throughput.
    Lung Cancer, 56(1): 69-75. [Abstract] [Full-text]
36. Lung cancer screening as a teachable moment for smoking cessation.
    Lung Cancer, 56(1): 125-34. [Abstract] [Full-text]
37. Common polymorphisms in D12S1034 flanking genes RASSF8 and BHLHB3 are not associated with lung adenocarcinoma risk.
    Lung Cancer, 56(1): 1-7. [Abstract] [Full-text]
38. Detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) using a fully automated system with a nano-scale engineered biomagnetite.
    Biosens Bioelectron, 22(9): 2282-8. [Abstract] [Full-text]
39. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
    Lung Cancer, 56(1): 25-33. [Abstract] [Full-text]
40. Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer.
    Lung Cancer, 56(1): 17-23. [Abstract] [Full-text]
41. Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk.
    Lung Cancer, 56(1): 9-15. [Abstract] [Full-text]
42. Deep-inspiration breath-hold kilovoltage cone-beam CT for setup of stereotactic body radiation therapy for lung tumors: initial experience.
    Lung Cancer, 56(1): 77-88. [Abstract] [Full-text]
43. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor.
    Lung Cancer, 56(1): 105-14. [Abstract] [Full-text]
44. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
    Lung Cancer, 56(1): 135-7. [Abstract] [Full-text]
45. Four-dimensional measurement of lung tumor displacement using 256-multi-slice CT-scanner.
    Lung Cancer, 56(1): 59-67. [Abstract] [Full-text]
46. Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells.
    Biochem Biophys Res Commun, 355(4): 993-9. [Abstract] [Full-text]
47. The attenuation of experimental lung metastasis by a bile acid acylated-heparin derivative.
    Biomaterials, 28(16): 2667-76. [Abstract] [Full-text]
48. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
    Cancer Gene Ther, 14(4): 431-9. [Abstract] [Full-text]
49. Improving outcomes for limited stage small cell lung cancer patients in Scotland with concomitant chemoradiation.
    Clin Oncol (R Coll Radiol), 19(3): 188-93. [Abstract] [Full-text]
50. Solitary fibrous tumor of the lung: a case report with a study of the aspiration biopsy, histopathology, immunohistochemistry, and autopsy findings.
    Diagn Cytopathol, 35(4): 239-44. [Abstract] [Full-text]
51. Risk factors for lung cancer in patients with scleroderma: a nested case-control study.
    Ann Rheum Dis, 66(4): 551-3. [Abstract] [Full-text]
52. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.
    Cancer Res, 67(6): 2809-15. [Abstract] [Full-text]
53. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas.
    Cancer Res, 67(6): 2517-25. [Abstract] [Full-text]
54. Fine mapping and candidate gene analyses of pulmonary adenoma resistance 1, a major genetic determinant of mouse lung adenoma resistance.
    Cancer Res, 67(6): 2508-16. [Abstract] [Full-text]
55. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.
    Cancer Res, 67(6): 2414-9. [Abstract] [Full-text]
56. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.
    Cancer Res, 67(6): 2396-401. [Abstract] [Full-text]
57. Molecular analysis of the CYP2F1 gene: identification of a frequent non-functional allelic variant.
    Mutat Res, 617(1): 79-89. [Abstract] [Full-text]
58. Investigating the genetic instability in the peripheral lymphocytes of 36 untreated lung cancer patients with comet assay and micronucleus assay.
    Mutat Res, 617(1): 104-10. [Abstract] [Full-text]
59. Antimetastatic activities of Selaginella tamariscina (Beauv.) on lung cancer cells in vitro and in vivo.
    J Ethnopharmacol, 110(3): 483-9. [Abstract] [Full-text]
60. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.
    Am J Respir Cell Mol Biol, 36(4): 398-408. [Abstract] [Full-text]
61. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis.
    Genes Dev, 21(6): 694-707. [Abstract] [Full-text]
62. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    J Clin Oncol, 25(9): 1027-32. [Abstract] [Full-text]
63. As depressing as it was predictable? Lung cancer, clinical trials, and the Medical Research Council in postwar Britain.
    Bull Hist Med, 81(1): 312-34. [Abstract] [Full-text]
64. Medicine and the public: the 1962 report of the Royal College of Physicians and the new public health.
    Bull Hist Med, 81(1): 286-311. [Abstract] [Full-text]
65. The effect of lung volume on nodule size on CT.
    Acad Radiol, 14(4): 476-85. [Abstract] [Full-text]
66. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance.
    Mol Immunol, 44(11): 2850-9. [Abstract] [Full-text]
67. Operative complications and early mortality after induction therapy for lung cancer.
    Eur J Cardiothorac Surg, 31(4): 714-7. [Abstract] [Full-text]
68. Interleukin 6 and interleukin 1 receptor antagonist as early markers of complications after lung cancer surgery.
    Eur J Cardiothorac Surg, 31(4): 719-24. [Abstract] [Full-text]
69. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not.
    Hum Pathol, 38(4): 555-63. [Abstract] [Full-text]
70. The sequence of vessel interruption during lobectomy: does it affect the amount of blood retained in the lobe?
    Eur J Cardiothorac Surg, 31(4): 711-3. [Abstract] [Full-text]
71. Increased perioperative N-terminal pro-B-type natriuretic peptide levels predict atrial fibrillation after thoracic surgery for lung cancer.
    Circulation, 115(11): 1339-44. [Abstract] [Full-text]
72. Offering a prognosis in lung cancer: when is a team of experts an expert team?
    J Epidemiol Community Health, 61(4): 308-13. [Abstract] [Full-text]
73. Computer-assisted lung nodule volumetry from multi-detector row CT: influence of image reconstruction parameters.
    Eur J Radiol, 62(1): 106-13. [Abstract] [Full-text]
74. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Cancer Chemother Pharmacol, 59(6): 725-32. [Abstract] [Full-text]
75. The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines.
    Cancer Chemother Pharmacol, 59(6): 781-7. [Abstract] [Full-text]
76. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    J Natl Cancer Inst, 99(6): 442-50. [Abstract] [Full-text]
77. Variation in the use of chemotherapy in lung cancer.
    Br J Cancer, 96(6): 886-90. [Abstract] [Full-text]
78. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
    Br J Cancer, 96(6): 857-63. [Abstract] [Full-text]
79. Loss of GFI1 impairs pulmonary neuroendorine cell proliferation, but the neuroendocrine phenotype has limited impact on post-naphthalene airway repair.
    Lab Invest, 87(4): 336-44. [Abstract] [Full-text]
80. Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma cell invasion.
    Exp Cell Res, 313(6): 1181-91. [Abstract] [Full-text]
81. Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation.
    Exp Cell Res, 313(6): 1215-24. [Abstract] [Full-text]
82. Platypnea-orthodeoxia syndrome after pneumonectomy relieved by mediastinal repositioning.
    Ann Thorac Surg, 83(4): 1524-6. [Abstract] [Full-text]
83. Rare pleural recurrence of typical pulmonary carcinoid tumor 30 years after lobectomy.
    Ann Thorac Surg, 83(4): 1523-4. [Abstract] [Full-text]
84. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer.
    Ann Thorac Surg, 83(4): 1245-9; discussion 1250. [Abstract] [Full-text]
85. Prognostic role of lymph node involvement in lung metastasectomy.
    J Thorac Cardiovasc Surg, 133(4): 967-72. [Abstract] [Full-text]
86. Awake pulmonary metastasectomy.
    J Thorac Cardiovasc Surg, 133(4): 960-6. [Abstract] [Full-text]
87. Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Future Oncol, 3(2): 131-9. [Abstract] [Full-text]
88. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17.
    J Immunol Methods, 321(1): 86-93. [Abstract] [Full-text]
89. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.
    Am J Respir Crit Care Med, 175(7): 712-9. [Abstract] [Full-text]
90. Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment.
    Thorax, 62(4): 335-40. [Abstract] [Full-text]
91. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay.
    Proc Natl Acad Sci U S A, 104(13): 5527-32. [Abstract] [Full-text]
92. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
    Cancer, 109(7): 1384-90. [Abstract] [Full-text]
93. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
    Cancer, 109(7): 1413-9. [Abstract] [Full-text]
94. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
    Ann Oncol, 18(4): 752-60. [Abstract] [Full-text]
95. Feasibility of percutaneous radiofrequency ablation for intrathoracic malignancies: a large single-center experience.
    Cancer, 109(7): 1397-405. [Abstract] [Full-text]
96. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients.
    Radiology, 243(1): 268-75. [Abstract] [Full-text]
97. CT Screening for lung cancer: diagnoses resulting from the New York Early Lung Cancer Action Project.
    Radiology, 243(1): 239-49. [Abstract] [Full-text]
98. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis.
    Am J Pathol, 170(4): 1337-47. [Abstract] [Full-text]
99. Primary small cell carcinoma of the nasal cavity with an unusual oral manifestation.
    J Oral Pathol Med, 36(4): 252-4. [Abstract] [Full-text]
100. Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide.
     Onkologie, 30(4): 201-4. [Abstract] [Full-text]
101. Observation of interfractional variations in lung tumor position using respiratory gated and ungated megavoltage cone-beam computed tomography.
     Int J Radiat Oncol Biol Phys, 67(5): 1548-58. [Abstract] [Full-text]
102. Is a single respiratory correlated 4D-CT study sufficient for evaluation of breathing motion?
     Int J Radiat Oncol Biol Phys, 67(5): 1352-9. [Abstract] [Full-text]
103. The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response.
     Int J Radiat Oncol Biol Phys, 67(5): 1360-9. [Abstract] [Full-text]
104. Is adaptive treatment planning required for stereotactic radiotherapy of stage I non-small-cell lung cancer?
     Int J Radiat Oncol Biol Phys, 67(5): 1370-4. [Abstract] [Full-text]
105. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
     Int J Radiat Oncol Biol Phys, 67(5): 1375-80. [Abstract] [Full-text]
106. Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts.
     Carcinogenesis, 28(4): 785-91. [Abstract] [Full-text]
107. Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs.
     Carcinogenesis, 28(4): 777-84. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.